한글목차

Buntanetap(구 명칭: ANVS401 또는 포시펜)은 합성 경구용 신경독성 응집 단백질(TINAPs) 억제제로서 신경독성 단백질의 수준을 감소시켜 뇌 내 독성을 감소시키는 경구용 저분자 화합물입니다. 독특한 작용기전으로 신경 퇴행의 주요 원인 중 하나인 APP/AB(APP), 타우/포스포타우(tau), a-시누클레인(aSYN) 등 여러 신경독성 단백질을 한꺼번에 억제하여 운동 기능을 개선할 수 있습니다.

미국 FDA는 초기 및 진행성 파킨슨병에 대한 Buntanetap의 임상 3상 시험에 대한 개발 지속을 승인했습니다. 현재 Buntanetap은 초기 파킨슨병에 대한 3상 임상시험을 진행 중이며, 2023년 말까지 임상시험을 완료할 예정입니다. 이 회사는 또한 알츠하이머병 및 기타 신경 퇴행성 질환에 대한 분타네탑을 개발하고 있습니다.

앞으로 몇 년동안 파킨슨병 시장 시나리오는 전 세계적으로 광범위한 조사와 의료비 지출 증가로 인해 변화할 것입니다. 각 회사는 질병을 치료/개선하기 위한 새로운 접근 방식에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, Buntanetap의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 파킨슨병에 대한 다른 신흥 제품들은 분타네탑과 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발 신약이 출시되면 시장에 큰 영향을 미칠 것으로 예상됩니다.

이 보고서는 주요 7개국의 파킨슨병 치료제 분타네탑(Buntanetap) 시장에 대해 조사했으며, 시장 개요, 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.

목차

제1장 보고서 서론

제2장 파킨슨병에서의 Buntanetap 개요

• 제품 상세
• 임상 개발
• 규제 마일스톤
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신흥 치료법)

제5장 Buntanetap 시장 평가

• 파킨슨병용 Buntanetap 시장 전망
• 주요 7개국 분석
  • 주요 7개국의 파킨슨병 치료제 Buntanetap 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight에 대해

제12장 보고서 구입 옵션

영문목차

"Buntanetap Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about buntanetap for Parkinson's disease in the seven major markets. A detailed picture of the buntanetap for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the buntanetap for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the buntanetap market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.

Drug Summary:

Buntanetap (previously known as ANVS401 or posiphen) is a synthetically produced oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which lowers the level of neurotoxic proteins and consequently less toxicity in the brain. Buntanetap is an orally available small molecule, and its unique mechanism of action allows it to inhibit multiple neurotoxic proteins-APP/AB (APP), tau/phospho-tau (tau), and a-Synuclein (aSYN)-that is one of the main causes of neurodegeneration at once and improve motor function.

The US FDA has green-lighted the continued development of Buntanetap into phase III for early and advanced Parkinson's disease. Presently buntanetap is being studied in a Phase III early Parkinson's disease study and the company expects to complete the trial by the end of 2023. The company is also developing buntanetap for Alzheimer's disease and other neurodegenerative conditions.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the buntanetap description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
• Elaborated details on buntanetap regulatory milestones and other development activities have been provided in this report.
• The report also highlights the buntanetap research and development activities in Parkinson's disease across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around buntanetap.
• The report contains forecasted sales of buntanetap for Parkinson's disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
• The report also features the SWOT analysis with analyst views for buntanetap in Parkinson's disease.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Buntanetap Analytical Perspective by DelveInsight

• In-depth Buntanetap Market Assessment

This report provides a detailed market assessment of buntanetap for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• Buntanetap Clinical Assessment

The report provides the clinical trials information of buntanetap for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence buntanetap dominance.
• Other emerging products for Parkinson's disease are expected to give tough market competition to buntanetap and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of buntanetap in Parkinson's disease.
• Our in-depth analysis of the forecasted sales data of buntanetap from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the buntanetap in Parkinson's disease.

Key Questions:

• What is the product type, route of administration and mechanism of action of buntanetap?
• What is the clinical trial status of the study related to buntanetap in Parkinson's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the buntanetap development?
• What are the key designations that have been granted to buntanetap for Parkinson's disease?
• What is the forecasted market scenario of buntanetap for Parkinson's disease?
• What are the forecasted sales of buntanetap in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to buntanetap for Parkinson's disease?
• Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?

Table of Contents

1. Report Introduction

2. Buntanetap Overview in Parkinson's disease

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and Efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Buntanetap Market Assessment

• 5.1. Market Outlook of Buntanetap in Parkinson's disease
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Buntanetap in the 7MM for Parkinson's disease
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Buntanetap in the United States for Parkinson's disease
  • 5.3.2. Market Size of Buntanetap in Germany for Parkinson's disease
  • 5.3.3. Market Size of Buntanetap in France for Parkinson's disease
  • 5.3.4. Market Size of Buntanetap in Italy for Parkinson's disease
  • 5.3.5. Market Size of Buntanetap in Spain for Parkinson's disease
  • 5.3.6. Market Size of Buntanetap in the United Kingdom for Parkinson's disease
  • 5.3.7. Market Size of Buntanetap in Japan for Parkinson's disease

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options